Why Exelixis Is Ready to Rebound

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis (NASDAQ: EXEL  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Exelixis and see what CAPS investors are saying about the stock right now.

Exelixis facts

Headquarters (founded)

South San Francisco, Calif. (1994)

Market Cap

$837.8 million

Industry

Biotechnology

Trailing-12-Month Revenue

$47.5 million

Management

Co-Founder/Chairman Dr. Stelios Papadopoulos
President/CEO Dr. Michael Morrissey

Trailing-12-Month Return on Equity

(76.3%)

Cash/Debt

$411.4 million / $335.7 million

Competitors

AstraZeneca
Genentech
GlaxoSmithKline

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 2,642 members who have rated Exelixis believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, JoeArizona, succinctly summed up the Exelixis bull case for our community:

Clinical trials are ongoing, and I don't anticipate much growth until the current round of trials show conclusive evidence that Cabozantinib is effective. But they already have one FDA approval under their belt, and as more come in the next few years, [Exelixis] will take off.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Exelixis may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2287832, ~/Articles/ArticleHandler.aspx, 9/21/2014 6:23:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement